CBL and juvenile myelomonocytic leukemia: The minimal effects of dosing c-CblA/− mice with 15 mg/kg was surprising given the promising findings from in vitro studies examining the inhibitory effects of dasatinib on cells from AML and JMML patients with c-Cbl mutations [18], [19].